Exclusive Chemaxon Interview Released – AI in Drug Discovery 2022 Conference Sponsor
SMi Reports: Chemaxon is releasing an interview ahead of joining SMi’s 3rd Annual AI in Drug Discovery Conference on March 14-15, 2022 in London as a key sponsor.
LONDON, LONDON, UK, March 5, 2022 /EINPresswire.com/ — In less than 2 weeks, SMi’s 3rd Annual Conference on AI in Drug Discovery will take place by bringing together senior experts from Principal Scientists, Business Development Managers, CEOs and VPs of AI in Drug Discovery.
SMi Group is delighted to publish a sponsor-focused speaker interview with Akos Tarcsay, Product Manager, Chemaxon Ltd ahead of the conference.
To see the full interview, go to http://www.ai-indrugdiscovery.com/PR4click on the ‘download center’ then watch ‘sponsor speaker interview – Chemaxon’
About Akos Tarcsay
Akos is the Calculator and Discovery Tools Product Manager at Chemaxon, a leading provider of software solutions and services for chemistry and biology. His team is responsible for providing a wide range of high quality physico-chemical predictions, structural and topological descriptors and clustering methods. Recently, the team has been active in streamlining machine learning to provide access to predictions based on local datasets.
Akos holds a Ph.D. in Computational Chemistry from Budapest University of Technology and Economics. He has over 10 years of experience in the computational chemistry and drug design industry gained at Gedeon Richter Plc and Chemaxon.
A excerpt from the exclusive interview with Akos Tarcsay:
The market for AI in drug discovery has evolved a lot in recent years, what key differences have you noticed in the last year regarding significant developments?
“AI has become accessible to a wider audience by making it easier to manage machine learning. Integration and MLOps have grown significantly, making the ecosystem more robust, repeatable and stable. Techniques available in the field scientist for some time are now closer to users who can harness the benefits of machine learning. Over the past year, generative modeling approaches have become the standard to be applied in drug discovery settings.”
What do you see as the biggest challenge personally facing drug discovery right now?
“The perception of machine learning results. This is a cultural shift; consumers of AI model results need to be educated about the benefits and possible limitations of the model to avoid confusion and distraction.”
What area of drug discovery do you work in and how have AI approaches helped drive the discovery process forward?
“I work with predictive modeling of targets and targets in the area of preclinical optimization. ADMET predictions are one of the areas I’m particularly interested in. Over the past year, I’ve been building cardiotoxicity models. We are a software solutions provider and help drug discovery teams in their efforts to rank ideas and find high-quality synthesis candidates using data and predictions.
The end goal is to increase the efficiency of drug discovery when balancing attributes and identifying successful drug candidates.”
Akos will speak at the AI in Drug Discovery conference on “Converting data into project team information» on the first day, covering:
• Creation of machine learning models for a large number of targets
• Demonstration of use cases from ADMET predictions: hERG and penetration models
• Comprehensive review of challenges, from data to actionable predictions
• Leverage the power of predictions in the integrated design system
The latest registered participants who will be attending the conference in less than 2 weeks include:
AI for Good Foundation, Astex Pharmaceuticals, AstraZeneca, Basecamp Research, Bayer AG, Benevolent AI, Boehringer Ingelheim, Cancer Research UK, CAS, CHARM Therapeutics, ICIS, Cresset Group, DISCNGINE, Envisagenics, Exscientia, GB Sciences, Genentech, GSK, Healx Limited, KSM, leadXpro AG, Merck, MultiOmic Health, Pfizer, Servier Pharmaceuticals, Sick Kids Childrens Hospital, Takeda, Verge Genomics, World Health Organization (WHO) and many more!
If you would like to join the conference, you can register your place by visiting http://www.ai-indrugdiscovery.com/PR4
Sponsored by: Chemaxon, Optibrium and Schrödinger
Interested in sponsoring, exhibiting or speaking at this event? Contact Andrew Gibbons, Sales Manager, on +44 (0) 20 827 6156 or email [email protected]
For media inquiries or to inquire about a press pass, contact Simi Sapal, Marketing Manager on +44 (0)20 7827 6162 or [email protected]
SMi’s 3rd Annual Conference on AI in Drug Discovery
Conference: March 14 – 15, 2022
—- TO FINISH —-
About SMi Group: Established since 1993, SMi Group is a global event production company specializing in business-to-business conferences, workshops, masterclasses and online communities. We create and organize events in the defense, security, energy, utilities, finance and pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking thought leaders and visionaries, enabling us to bring our communities together to learn, engage, share and network. More information can be found at http://www.smi-online.co.uk
write to us here